The pentapeptide QYNAD does not inhibit neuronal network activity

Canadian Journal of Neurological Sciences

Volumn 32, Issue 3, 2005, Pages 344-348

  Otto, F ^a   Kieseier, B C ^a   Gortz P ^a   Hartung, H P ^a   Siebler, Mario ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; PENTAPEPTIDE; TETRODOTOXIN;

ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; GUILLAIN BARRE SYNDROME; LABORATORY TEST; MICROELECTRODE; MULTIPLE SCLEROSIS; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM CURRENT;

EID: 24144440009     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100004248     Document Type: Article

References (16)

1. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nature Rev Neurosci 2002;3:291-301.
2. Alcazar A, Regidor I, Masjuan J, Salinas M, Alvarez-Cermeno JC. Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2000;104(1):58-67.
3. Brinkmeier H, Wollinsky KH, Seewald MJ, et al. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels. Neurosci Lett 1993;156:172-175.
4. Köller H, Buchholz J, Siebler M. Cerebrospinal fluid from multiple sclerosis patients inactivates neuronal Na+ current. Brain 1996;119:457-463.
5. Kieseier BC, Kiefer R, Gold R, et al. Advances in immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004 (in press).
6. Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rüdel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 2000;6(7):808-811.
7. Meuth SG, Budde T, Duyar H, et al. Modulation of neuronal activity by the endogenous pentapeptide QYNAD. Eur J Neurosci 2003;18:1-10.
8. Cummins TR, Renganathan M, Stys PK, et al. The pentapeptide QYNAD does not block voltage-gated sodium channels. Neurology 2003;60(2):224-229.
9. Quasthoff S, Pojer C, Mori A, et al. No blocking effect of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve. Neurosci Lett 2003;352(2):93-96.
10. Gross GW, Rhoades BK, Azzazy HM, Wu MC. The use of neuronal networks on multielectrode arrays as biosensors. Biosens Bioelectron 1995;10:553-567.
11. Otto F, Görtz P, Fleischer W, Siebler M. Cryopreserved rat cortical cells develop functional neuronal networks on microelectrode arrays. J Neurosci Methods 2003;128:173-181.
12. Brinkmeier H, Aulkemeyer P, Bechter K, Wollinsky KH, Rüdel R. Concentration of the Na+ channel blocker QYNAD determined in CSF and serum of GBS patients using ion trap mass spectroscopy. Pflügers Arch 2002;443(19):S367.
13. Aulkemeyer P, Rüdel R, Tumani H, Brinkmeier H. Ion trap mass spectroscopy shows that the Na+ channel blocker QYNAD exists in the CSF of MS patients but is absent in the CSF of ALS patients. Pflügers Arch 2002;443(19):S190.
14. Padmashri R, Chakrabarti KS, Sahal D, et al. Functional characterization of the pentapeptide QYNAD on rNAv1.2 channels and its NMR structure. Pflügers Arch 2004;447:895-907.
15. Shah BS, Stevens EB, Pinnock RD, Dixon AK, Lee K. Developmental expression of the novel voltage-gated sodium channel auxiliary subunit b3, in rat CNS. J Physiol 2001;534:763-776.
16. Tumani H, Aulkemeyer P, Süssmuth S, Rüdel R, Brinkmeier H. Das endogene Na-Kanal-blockierende Pentapeptid Gln-Tyr-Asn-Ala-Asp (QYNAD) bei multipler Sklerose: Erhöhte Liquorkonzentration korreliert nicht mit klinischer Beeinträchtigung oder MRT-Läsionen. Akt. Neurol 2001;28:S87.